An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin

Pharmacogenetics

Volumn 7, Issue 5, 1997, Pages 355-360

  Tybring, Gunnel ^a   Nordin, Jan ^a   Bergman, Tomas ^b   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CYP2C19; Cysteine conjugate; S mephenytoin

Indexed keywords

CYSTEINE CONJUGATE; MEPHENYTOIN;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MEPHENYTOIN; PHENOTYPE;

LEPUS;

EID: 0030799213     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199710000-00003     Document Type: Article

References (10)

1. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994: 269, 15419-15422.
2. Harada S, Abei M. Human gluthatione transferase. In: Kalow W. editor. Pharmacogenetics of drug metabolism. New York: Pergamon press, 1992: 249-259.
3. Küpfer A, Roberts RK, Schenker S, Branch RA. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981: 218, 193-198.
4. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotype in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989: 45, 495-499.
5. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992: 2, 241-243.
6. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984a: 36, 773-780.
7. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chrom 1984b: 307, 121-127.
8. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987: 15, 277-279.
9. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon press, 1992: 657-685.
10. Zhang Y, Blouin RA, McNamara P, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S/R-mephenytoin ratio in pharmacogenetics studies. Br J Clin Pharmacol 1991: 31, 350-352.